Product Overview?
Ozenoxacin (CAS: 245765-41-7) is a ?non-fluorinated quinolone antibiotic? with the molecular formula ?C??H??N?O?? and molecular weight ?363.41??13. It acts as a potent inhibitor of ?DNA gyrase and topoisomerase IV?, targeting Gram-positive bacteria like Staphylococcus aureus and Streptococcus pyogenes?14. Primarily used for ?topical treatment of impetigo? in patients aged ≥2 months, it is available in cream formulations for skin infections?13.

? ?Key Advantages?
? ?High Purity?: ≥99% (HPLC/GC verified), ensuring compliance with pharmaceutical standards?13.
? ?Broad-Spectrum Activity?: Effective against ?MRSA and MSSA? with MIC values ranging from ?0.008–4 mg/L??14.
? ?Stable Storage?: Maintains stability at ?2–8°C? (protected from light)?13.

?? ?Application Fields?

• ?Dermatology?: First-line therapy for ?impetigo? caused by S. aureus?14.

• ?Antibiotic Research?: Study of resistance mechanisms in Gram-positive pathogens?45.

• ?Pharmaceutical Synthesis?: Intermediate for novel antibacterial agents?37.

?? ?Quality Certifications?

• Produced in ?GMP-certified facilities? adhering to ?USP/EP/BP standards??13.

• Quality verified via ?HPLC, NMR, and mass spectrometry??35.

• Complies with ?MSDS guidelines? for safe handling and transport?35.

?? ?Market Insights?
The global topical antibiotics market is projected to grow at ?CAGR 5.1%?, reaching ?$7.2B by 2030?, driven by rising skin infections and demand for localized treatments?14. Ozenoxacin’s efficacy against resistant strains positions it as a critical therapeutic option?45.